$LLY Catalyst Posts
September 22, 2026Single-day social intelligence recap and verified catalyst posts · ← Back to $LLY Profile · Market Rankings
💬 Curated Viral Posts & Community Evidence
1 source posts analyzed· 2026-09-22T11:27:58+00:00$VKTX this is how VK2735 stands against $LLY tirzepatide/retatrutide 1) VK2735’s weekly 17.5 mg cohort reached 22% weight loss at Week 33 with no plateau Tirzepatide (Zepbound) Phase 3: ~22.5% at Week 72 Retatrutide Phase 2: ~24% at Week 48 2) VK2735 is already in the same
AI visual analysis: The image displays Table 1, titled "Adverse events in key global SURMOUNT studies for overweight/obesity management," comparing side effects across four SURMOUNT trials (SURMOUNT-1, -2, -3, and -4) for tirzepatide (TZP) and placebo groups, listing events like intervention counts, participants with ≥1 AE, deaths, and discontinuations over specified weeks. This table supports the post's comparison of $VKTX's VK2735 to Eli Lilly's ($LLY) tirzepatide (SURMOUNT trials) by showing the safety/tolerability profile of the relevant comparator drug across its clinical program.